

33
Cont

in Figure 34. The numbers in Figure 34 indicate the positions of Cys residues and the brackets indicate disulfide linkages inferred by analogy to those present in TIMP and probably MI as well. The arrowheads indicate positions of Lys and Arg residues. Note that the fragment 133-170 produced by plasmin cleavage has two internal disulfide bonds (Cys 133-Cys 138 and Cys 146-Cys 167) but no covalent linkages to fragment 1-132 or fragment 171-194. As suggested above, the disulfide bond Cys 128-Cys 175 would keep fragments 1-132 and 171-194 covalently linked after excision of fragment 133-170 by plasmin.

Please insert the enclosed sequence after page 106 of the application.

IN THE CLAIMS:

✓ Please cancel claims 1-37 without prejudice or disclaimer of the subject matter recited therein. Please add the following claims:

- 40. The antibody according to claim 38, comprising a detectable label.
41. A hybridoma cell secreting an antibody according to claim 39.
42. A method for detecting metalloproteinase inhibitor in a biological sample, comprising
- contacting an antibody specifically binding to metalloproteinase inhibitor with said biological sample; and
- measuring the binding of the antibody to metalloproteinase inhibitor.
43. The method according to claim 42, wherein the antibody comprises a detectable label.
44. The method according to claim 42, wherein the antibody is a monoclonal antibody.

34

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

45. The method according to claim 42, wherein the method is a radioimmunoassay.
46. The method according to claim 42, wherein the method is a enzyme-linked immunoassay.
47. The method according to claim 42, wherein the metalloproteinase inhibitor is a human metalloproteinase inhibitor.
48. The method according to claim 42, wherein the biological sample is selected from a tissue, serum, and urine. 6
49. The method according to claim 42, wherein the biological sample is a tumor.
50. A kit for detecting metalloproteinase inhibitor in a biological sample comprising an antibody specifically binding to metalloproteinase inhibitor.
51. The kit according to claim 50, wherein the antibody is comprises a detectable label.
52. The kit according to claim 50, wherein the antibody is a monoclonal antibody.--

34
cont